Ilaris Complete Response Letter Raises Questions About The Validity of Priority Review Vouchers
Executive Summary
What’s a Priority Review Voucher worth? That’s a complicated question now that the first voucher used on an application, from drug maker Novartis AG for Ilaris (canakinumab), has received a complete response letter from US regulators.